AgomAb Therapeutics NV (AGMB)
Data as of , from SEC Form 4 filings.
See up to 3 months of AGMB. The 7-day demo opens the 1M and 3M ranges and puts AGMB on your watchlist.
Start 7-day demoLatest AGMB insider trades
David R. Epstein - DirectorOpen-market purchase$44K- David R. Epstein
About AgomAb Therapeutics NV (AGMB)
The SEC lists AgomAb Therapeutics NV under CIK 0002020932, in biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector. Its offering priced on 6 February 2026 and it trades on NASDAQ.
AGMB Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 10 | 46,000 | $400K |
| Grant or award | 2 | 113,810 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
AGMB insider transactions (Form 4)
127 Form 4 filings on record, the earliest from Sep 15, 2026, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David R. Epstein - Director | Open-market purchase | Common shares | 5,000 | $8.86 | $44K | |
| David R. Epstein - Director | Open-market purchase | Common shares | 5,000 | $8.90 | $45K | |
| David R. Epstein - Director | Open-market purchase | Common shares | 5,000 | $8.90 | $45K | |
| David R. Epstein - Director | Open-market purchase | Common shares | 5,000 | $8.57 | $43K | |
| David R. Epstein - Director | Open-market purchase | Common shares | 5,000 | $8.70 | $44K | |
| Pierre Thadee Victor Kemula - Officer | Open-market purchase | Common shares | 3,000 | $8.67 | $26K | |
| Pierre Thadee Victor Kemula - Officer | Open-market purchase | Common shares | 5,000 | $8.57 | $43K | |
| Pierre Thadee Victor Kemula - Officer | Open-market purchase | Common shares | 2,000 | $8.54 | $17K | |
| Tim Jasper Knotnerus - Officer | Open-market purchase | Common shares | 6,000 | $8.48 | $51K | |
| Tim Jasper Knotnerus - Officer | Open-market purchase | Common shares | 5,000 | $8.70 | $44K | |
 Marino Garcia - Director | Grant or award | Stock Option (Right to Buy) | 57,482 | $0.00 | - | |
 Naimish Patel - Director | Grant or award | Stock Option (Right to Buy) | 56,328 | $0.00 | - |
AGMB insider trading FAQ
What is the latest insider trade for AGMB?
AgomAb Therapeutics NV (AGMB) had 7 insider filings in the last 90 days, with the most recent on 22 October 2026. The full record for AGMB runs to 7 Form 4 filings, the earliest from 15 September 2026. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying AGMB stock?
10 insider purchases of AGMB were filed in the last 90 days, totaling $400K.
How many insiders are selling AGMB stock?
No insider sales of AGMB were filed in the last 90 days.
Where can I see AGMB SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects AGMB Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
7The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - David R. Epstein view on EDGAR
- - David R. Epstein view on EDGAR
- - David R. Epstein view on EDGAR
- - Pierre Thadee Victor Kemula view on EDGAR
- - Tim Jasper Knotnerus view on EDGAR
- - Marino Garcia view on EDGAR
- - Naimish Patel view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where AGMB's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow AGMB with a 7-day demo
- AGMB on your watchlist
- Every AGMB Form 4 filing on record
- Up to 3 months of AGMB price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
